HomeCompareDHROX vs PFE

DHROX vs PFE: Dividend Comparison 2026

DHROX yields 8.96% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $14.9K in total portfolio value· pulled ahead in Year 10
10 years
DHROX
DHROX
● Live price
8.96%
Share price
$22.33
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36.2K
Annual income
$1,575.70
Full DHROX calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — DHROX vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDHROXPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DHROX + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DHROX pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DHROX
Annual income on $10K today (after 15% tax)
$761.31/yr
After 10yr DRIP, annual income (after tax)
$1,339.35/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $21,789.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DHROX + PFE for your $10,000?

DHROX: 50%PFE: 50%
100% PFE50/50100% DHROX
Portfolio after 10yr
$43.6K
Annual income
$14,393.12/yr
Blended yield
32.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DHROX
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DHROX buys
0
PFE buys
0
No recent congressional trades found for DHROX or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDHROXPFE
Forward yield8.96%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$36.2K$51.1K
Annual income after 10y$1,575.70$27,210.54
Total dividends collected$12.4K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DHROX vs PFE ($10,000, DRIP)

YearDHROX PortfolioDHROX Income/yrPFE PortfolioPFE Income/yrGap
1$11,596$895.66$9,161$701.38+$2.4KDHROX
2$13,378$970.63$8,610$859.79+$4.8KDHROX
3$15,361$1,046.56$8,366$1,081.25+$7.0KDHROX
4$17,559$1,123.08$8,483$1,405.66+$9.1KDHROX
5$19,988$1,199.82$9,084$1,907.24+$10.9KDHROX
6$22,664$1,276.43$10,418$2,732.78+$12.2KDHROX
7$25,603$1,352.61$13,007$4,193.56+$12.6KDHROX
8$28,823$1,428.06$18,010$7,005.87+$10.8KDHROX
9$32,343$1,502.50$28,216$12,979.89+$4.1KDHROX
10← crossover$36,183$1,575.70$51,081$27,210.54$14.9KPFE

DHROX vs PFE: Complete Analysis 2026

DHROXStock

The investment seeks to provide long-term capital appreciation. The fund normally invests its assets primarily in U.S. equity securities of any size that Diamond Hill Capital Management, Inc. believes are undervalued. It may also invest up to 40% of its net assets in non-U.S. equity securities, including equity securities in emerging market countries. The Adviser focuses on estimating a company&#39;s value independent of its current stock price. To estimate a company&#39;s value, the Adviser concentrates on the fundamental economic drivers of the business. The fund may sell securities short.

Full DHROX Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DHROX vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DHROX vs SCHDDHROX vs JEPIDHROX vs ODHROX vs KODHROX vs MAINDHROX vs JNJDHROX vs MRKDHROX vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.